Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.
EP. 1: Biomarker Testing in AML
Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.
Watch
EP. 2: Frontline Treatment Options in AML
A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.
EP. 3: VIALE-A Trial: Acute Myeloid Leukemia
Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.
EP. 4: Considerations in Choosing Venetoclax for AML
An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.
EP. 5: Future of AML Management
Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.
